In a bid to combat the “medical-speak” problems plaguing Indian generics, India has been testing new drugs from two of the top players in the industry.
In a joint report, HealthInfoIndia and Medical Technology Monitor India (MTRI) analysed the clinical trials for four Indian genericoins: Ruparibin, Rupaginal, Dronabinol, and Nurofen, and found the results were generally encouraging.
Both genericoin companies had successfully developed a series of promising clinical trials with the exception of Dronabemol, which had an overall poor clinical trial record and was pulled from the market.
However, India’s overall record for clinical trials was impressive: the Indian National Drug and Device Authority (NMDAA) had successfully completed a clinical trial with Nurofin for a period of four years in 2013, and had successfully conducted another phase of clinical trials in India with the drug in the second quarter of 2017.
However this was only the beginning of India’s drug development.
India is also looking to the US and other developed markets to be its next step in developing genericoinficlone drugs.
“This is the first time that the NMDAA has completed a phase I clinical trial in India, and the country’s pharmaceutical industry is now ready to take the next step,” said MTRI President and CEO, Dr. Deepak Gupta.
Gupta said the NMCA’s Phase II clinical trial was a success and has demonstrated that the Indian pharma industry is ready to move forward in a competitive environment.
“In addition to this, the NMIA has also conducted two phase III clinical trials that have yielded impressive results, with a Phase IV clinical trial planned for the second half of 2017,” Gupta said.
Nurofen has also been approved for Phase II trials in the US.
Gupta also said that India’s Phase III clinical trial data has been very promising.
“The Indian pharmaceutical industry has shown that it is ready for Phase III trials, and this is in line with our expectations.
As of now, Nurofrein has successfully passed all Phase II and Phase III tests and has a positive overall clinical trial rate.
India’s pharmaceutical companies are now focused on developing and delivering medicines to patients in the developing world.”
The report also found that Indian generic companies are in fact investing in their clinical trials.
“There has been a significant investment by Indian genericais in their Phase II or III clinical tests,” Gupta added.
“Many of these companies have already conducted phase II and III trials and have reported positive results, but these are only preliminary data and we need to see the final clinical trial results before we can say for sure if these results are conclusive or not.”
Gupta said that he believes Indian generick drugs are ready for market in India and the US, and he expects them to become a major part of the Indian drug market in the near future.
“NMDA is very proactive in evaluating and evaluating Indian generic companies in the development of their medicines, and we believe this will be a positive trend for Indian generican companies,” Gupta continued.
The report highlighted the potential for Indian drug companies to create a new industry in the global generic market, as well as the importance of India for drug discovery. “
As the world’s largest drug market, India represents a large potential market for the global pharma companies,” he added.
The report highlighted the potential for Indian drug companies to create a new industry in the global generic market, as well as the importance of India for drug discovery.
“With over 200,000 pharmaceutical companies, India already has a large and active pharmaceutical market, and is likely to be a leader in this space in the future.
Indian companies will be the main players in this market and this will open new doors for Indian companies in terms of research and development, manufacturing, distribution, and marketing of medicines,” Gupta concluded.
Follow us on Twitter: @AjaxHealth and @AJAXHealth_InDepth for more information.
Follow AJAXHealth and India for the latest news.
More to come